Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CD20 Positive Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma, CD20 Positive, Childhood Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine, Filgrastim, Fludarabine, Methotrexate, Rituximab, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
48
States / cities
Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions
Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3, Part 2, Cohort 1, Part 2, Cohort 2
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
New York, New York • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
ABP 798, Rituximab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Encinitas, California • Mount Sterling, Kentucky • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced May 21, 2026, 7:14 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
Tahir Latif
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
Interventions
rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, filgrastim, laboratory biomarker analysis
Biological · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced May 21, 2026, 7:14 PM EDT
Suspended Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Rituximab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
aldesleukin, allogeneic natural killer cells, rituximab, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
pharmacological study, rituximab, dexamethasone, laboratory biomarker analysis
Other · Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced May 21, 2026, 7:14 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive, Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL)
Interventions
Rituxan, motexafin gadolinium, 111Indium-Zevalin and 90Yttrium-Zevalin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions
beta-glucan, rituximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Campath-1H, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
pegfilgrastim, rituximab, flow cytometry, biopsy, immunohistochemistry staining method, western blotting
Biological · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
Interventions
rituximab, ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
4
States / cities
Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
CD20 Positive Non Hodgkin Lymphoma
Interventions
CPO107
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
ACTR087, rituximab
Biological
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Gilbert, Arizona • New Haven, Connecticut • Maywood, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced May 21, 2026, 7:14 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative, Pleomorphic Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, t(11;14)(q13;q32)
Interventions
Acalabrutinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 7:14 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
CAMPATH (alemtuzumab)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
10
States / cities
Colorado Springs, Colorado • Ocala, Florida • Park Ridge, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced May 21, 2026, 7:14 PM EDT